The BaxHTN study investigated the efficacy and safety of baxdrostat in patients with uncontrolled or resistant hypertension who are taking multiple antihypertensive drugs.[3] After 12 weeks of treatment with baxdrostat 1 mg or 2 mg daily, there was a placebo-adjusted decrease in sitting systolic blood pressure of 8.7 mmHg with 1 mg and 9.8 mmHg with 2 mg (both p<0.0001).[3] In ambulatory monitoring of 24-hour and nocturnal systolic pressure, the 2 mg dose decreased by 16.9 mmHg and 11.7 mmHg compared to placebo.[3] About 40% of patients achieved a target systolic pressure below 130 mmHg.[1] No cases of adrenal insufficiency or other unexpected safety findings were reported.[3] Effects were consistent in both uncontrolled and resistant hypertension subgroups.[3] Baxdrostat inhibits the synthesis of aldosterone, which contributes to a decrease in pressure in patients where standard treatment fails.[2][3]